Weichai Power (02338) had repurchased approximately 50,252,500 A-shares by the end of March.
Weichai Power (02338) announced the progress of its A-share repurchase. As of March 31, 2026, the company has repurchased a total of 50,252,475 A-shares through its repurchase special securities account using centralized bidding trading method, representing approximately 0.58% of the company's total share capital. The highest transaction price was RMB 15.43 per share, the lowest transaction price was RMB 14.57 per share, and the total amount paid was approximately RMB 761 million (excluding transaction costs). This repurchase complies with relevant laws and regulations and the company's established share repurchase plan.
Weichai Power (02338) announced the progress of the repurchase of A shares. As of March 31, 2026, the company has repurchased a total of 50,252,475 A shares through a dedicated securities account by means of centralized bidding trading, accounting for approximately 0.58% of the company's current total share capital. The highest transaction price was RMB 15.43 per share and the lowest transaction price was RMB 14.57 per share. The total amount paid was approximately RMB 761 million (excluding transaction costs). This repurchase complies with relevant laws and regulations and the company's established share repurchase plan requirements.
Related Articles

Far East Smarter Energy subsidiary won a total of 1.821 billion yuan in contract orders in March.

Noah Holdings (06686) spent approximately $44.84 million to repurchase 225,730 shares on March 31st.

Johnson & Johnson(JNJ.US) has obtained clinical approval in China for a new class 1 drug, intending to develop a treatment for multiple myeloma.
Far East Smarter Energy subsidiary won a total of 1.821 billion yuan in contract orders in March.

Noah Holdings (06686) spent approximately $44.84 million to repurchase 225,730 shares on March 31st.

Johnson & Johnson(JNJ.US) has obtained clinical approval in China for a new class 1 drug, intending to develop a treatment for multiple myeloma.






